top of page
NeuroSigma Announces Patent Application Protecting Use of Trigeminal Nerve Stimulation to Include Treatment of Dyslexia and Other Neurodevelopmental Disorders
LOS ANGELES, January 22, 2024 (GLOBE NEWSWIRE) -- NeuroSigma, Inc. , a Los Angeles-based bioelectronics company commercializing the...
Clinical Trial of NeuroSigma’s Monarch eTNS System for ADHD at King’s College London Completes Enrollment.
ATTENS (ADHD trial of external trigeminal nerve stimulation) Project , led by Professor Katya Rubia at the Institute of Psychiatry,...
Telix to Acquire Next-Generation Therapeutic Assets and Innovative Biologics Technology Platform(PRNewsfoto/Telix Pharmaceuticals Limited)
MELBOURNE, Australia and INDIANAPOLIS, Jan. 13, 2025 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Nasdaq: TLX, Telix, the...
Press
bottom of page